Teva Pharmaceuticals Settles $450M Kickback and Price-Fixing Allegations

The settlement resolves claims that Teva violated federal statutes by manipulating drug prices and copay assistance programs.

Teva Pharmaceuticals agreed to pay $450 million to settle allegations of violating the Anti-Kickback Statute and the False Claims Act.
The settlement addresses two schemes: one involving copay kickbacks for the multiple sclerosis drug Copaxone, and another involving price-fixing of generic drugs.
From 2006 to 2017, Teva allegedly coordinated with third parties to cover Medicare copays for Copaxone, while simultaneously increasing its price.
The price-fixing allegations involve Teva conspiring with other manufacturers to set prices for drugs like pravastatin, clotrimazole, and tobramycin.
This resolution is part of a broader effort by the Justice Department to combat pharmaceutical price-fixing and kickback schemes, having recovered over $1 billion since 2017.